Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Trigonelline reduced diabetic nephropathy and insulin resistance in type 2 diabetic rats through peroxisome proliferator-activated receptor-γ. 31363374 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE To investigate this hypothesis, db/db diabetic mice were used to establish a DKD model and the PPARγ agonist rosiglitazone was employed to induce PGC‑1α expression in vivo. 29344670 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE For this purpose, we performed a microarray analysis on kidneys of 3-wk-old peroxisome proliferator-activated receptor-γ (PPARγ)-null and AZIP/F1 mice, which are two models of diabetic nephropathy due to lipodystrophy. 29488390 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE Quantitative results of reverse transcriptase polymerase chain reaction demonstrated that compared with the placebo, CQ10 administration upregulated gene expression of peroxisome proliferator-activated receptor-γ (P = .02) in peripheral blood mononuclear cells of the patients with DN. 29421772 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Peroxisome proliferator activated receptor-gamma (PPAR-γ) is implicated in several metabolic syndromes including Diabetic Nephropathy, besides obesity, insulin insensitivity, dislipidemia, inflammation, and hypertension. 28539091 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE We and others have shown that SIRT1 exerts renoprotective effects in DKD in part through the deacetylation of transcription factors involved in the disease pathogenesis, such as p53, FOXO, RelA/p65NF-κB, STAT3, and PGC1α/PPARγ. 30386303 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE The Impact of Peroxisome Proliferator-Activated Receptor Gamma and Its Interaction with Abdominal Obesity on Diabetic Nephropathy in Chinese Han. 28013303 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE The aim of the present study is to identify the regulation of lncRNA TUG1 on extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ, and investigate the underlying mechanisms in progression of DN. 28137588 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Herein, we asked whether miR-27a mediates podocyte injury through PPARγ/β-catenin signaling in DN. 28277542 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease CTD_human Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system. 28182703 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Thus, in line with the role of PPARγ in metabolic homeostasis, Pparg null-mice first represent a potent model for studying the initiation and the development of diabetic nephropathy. 28182703 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE These findings demonstrate a novel mechanism that CDK5 increases tubulointerstitial fibrosis by activating the ERK1/2/PPARγ pathway and EMT in DN. 27145370 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Thus, we propose a novel role of the miR-27a-PPARγ axis in fostering the progression toward more deteriorated renal TIF in DN. 27351287 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE EGFR inhibition may be a therapeutic strategy in the treatment of diabetic nephropathy and in limiting salt and water retention, which currently restricts the use of PPARγ agonists. 23370527 2013
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE This meta-analysis suggests that the Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians. 22103651 2012
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE The +A2962G of PPARGC1A and the 3 polymorphisms of PPARG were not associated with DN. 19900151 2010
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. 19837787 2010
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. 19506043 2009
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease LHGDN We examined the relationship between two PPAR-gamma gene polymorphisms, namely the P12A and C161T, and cardiovascular disease in patients with diabetic nephropathy. 18417957 2008
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE We conclude that P12A and C161T polymorphisms of the PPAR-gamma gene are important predictors of cardiovascular event in patients with diabetic nephropathy. 18417957 2008
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma 2 gene is suggested to associate with diabetic nephropathy and cardiovascular disease in type 2 diabetes. 18467141 2008
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease RGD In the present study, we investigated the effect and molecular mechanism of the PPARgamma agonist, pioglitazone, on the progression of diabetic nephropathy in type 2 diabetic rats. 18388116 2008
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population. 17493550 2007
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease LHGDN The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population. 17493550 2007
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE We aim to investigate Turkish type 2 diabetic patients with/without diabetic nephropathy and healthy group and examined the contribution of the G/C exon 2 and T/C exon 6 of the PPAR gamma gene polymorphism to the development of diabetic nephropathy. 17681394 2007